TO-O-1001 for POAG and OH
A patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension.
The first “Eye Drops” formulation ever be brought into wet AMD market for patients’ ease of use and overall therapeutic benefit.
TO-O-1003 for Dry eye
The unique dual action pathway (promoting tear secretion and anti-inflammatory response) can effectively reduce the discomfort of dry eye patients.
TO-O-1004 for Post-Operative Pain and Inflammation with Cataract Surgery
Aiming to treat the post-operative inflammation and improve the quality of life after surgery.
TO-O-1005 for Presbyopia
Aiming to restore accommodation ability of lens for Presbyopia patients.
TO-O-1006 for Dry AMD
Special formulation to assist the elimination of drusen, and delay dryAMD progression.